Skip to content
Inciteful Med

Protecting Your Whole Body: Multisystem Care and Monitoring

Last updated:

MELAS is a multisystem disorder that requires a proactive, multidisciplinary care team. Because mitochondrial dysfunction impairs energy production across the body, patients need regular monitoring to protect their heart, hearing, gut, kidneys, and endocrine system.

Key Takeaways

  • • MELAS requires proactive, multisystem monitoring because mitochondrial energy failure can affect almost every organ in the body.
  • • Regular heart monitoring with echocardiograms and EKGs is crucial to detect thickening of the heart muscle and electrical rhythm issues early.
  • • Sensorineural hearing loss is highly common and progressive, making routine audiology exams an essential part of care.
  • • Severe bloating, nausea, and digestive issues may indicate Chronic Intestinal Pseudo-Obstruction (CIPO), a serious complication that requires immediate management.
  • • A multidisciplinary care team, coordinated among specialists like neurologists, cardiologists, and endocrinologists, is the standard approach for managing MELAS.

While the most visible symptoms of MELAS often involve the brain and muscles, the condition can affect almost every organ system in the body. Because mitochondria provide energy for every cell, a failure in energy production can cause a “domino effect” across multiple systems [1][2].

Managing MELAS effectively means moving from a reactive approach—treating problems only when they appear—to a proactive, multisystem monitoring approach.

The Heart: Monitoring Muscle and Rhythm

The heart is one of the most energy-demanding organs in the body, making it particularly vulnerable to mitochondrial failure [3].

  • Hypertrophic Cardiomyopathy: This is a thickening of the heart muscle, which can make it harder for the heart to pump blood effectively [3][4]. Over time, this may lead to heart failure or structural damage [3][5].
  • Conduction Defects: Some patients develop “electrical” issues, such as Wolff-Parkinson-White (WPW) syndrome—a condition where an extra electrical pathway in the heart causes a rapid or irregular heartbeat [6][7].
  • Monitoring: Regular echocardiograms (ultrasounds of the heart) and EKGs (electrical heart tracings) are essential to catch these changes early [7][3].

Sensory Health: Hearing and Vision

Mitochondrial dysfunction often targets the delicate nerves and cells responsible for our senses.

  • Hearing Loss: Sensorineural hearing loss (SNHL) is one of the most common features of MELAS, occurring in up to 78% of cases [8][2]. It is often progressive and may eventually require hearing aids or cochlear implants [8][9].
  • Vision Issues: Carriers of the m.3243A>G mutation may develop retinopathy (damage to the back of the eye) or macular dystrophy, which can lead to vision loss [10][11].

The Gut: Intestinal Pseudo-Obstruction (IPO)

One of the more serious, yet less discussed, complications is Chronic Intestinal Pseudo-Obstruction (CIPO) [12][13].

  • What it is: This occurs when the nerves and muscles of the gut stop working correctly. It creates the symptoms of a severe bowel blockage (nausea, massive bloating, vomiting) even when no physical blockage exists [12][14].
  • The Risk: Recurrent IPO is often a sign of severe metabolic stress and has been linked to a higher risk of subsequent stroke-like episodes and neurological decline [13].

Hormones and Kidneys: Diabetes and Filtration

  • Diabetes Mellitus: Approximately 85% of people with the m.3243A>G mutation will develop diabetes by age 70 [15][16]. This is often referred to as Maternally Inherited Diabetes and Deafness (MIDD) [10][17].
  • Hypoparathyroidism: In rare cases, the body stops producing enough parathyroid hormone, leading to dangerously low calcium levels and potentially causing calcifications in the brain [18].
  • Kidney Disease: The kidneys are highly sensitive to energy deficits. This can manifest as Focal Segmental Glomerulosclerosis (FSGS)—a condition where scar tissue forms on the tiny filtering units inside the kidneys, impairing their ability to clean the blood [19][20].

Building Your Care Team

Because MELAS is a multisystem condition, no single doctor can manage it alone. A multidisciplinary care team ensures that every system is monitored [2][1].

Specialist Role in Your Care
Neurologist Manages seizures, stroke-like episodes, and cognitive health [2][21].
Cardiologist Monitors heart muscle thickness and electrical rhythms [7][3].
Endocrinologist Manages diabetes and other hormonal issues like hypoparathyroidism [22][18].
Audiologist Performs regular hearing tests and coordinates hearing support [8][22].
Gastroenterologist Manages gut motility and monitors for pseudo-obstruction [22][13].
Nephrologist Monitors kidney function and manages protein in the urine [2][23].
Geneticist Provides guidance on mutation levels (heteroplasmy) and family screening [24][25].
Nutritionist Helps design a diet that supports energy needs and gut health [26][12].

If you need to review the basics, return to the Understanding MELAS Home Page.

Frequently Asked Questions

What kind of doctors should be on my MELAS care team?
A MELAS care team should be multidisciplinary because the condition affects many parts of the body. Your team should typically include a neurologist, cardiologist, endocrinologist, audiologist, gastroenterologist, and nephrologist to proactively monitor different organ systems.
How does MELAS affect the heart?
MELAS can cause hypertrophic cardiomyopathy, which is a thickening of the heart muscle, as well as electrical rhythm issues. Regular echocardiograms and EKGs are essential to catch and manage these heart changes early on.
Can MELAS cause severe stomach and bowel problems?
Yes, MELAS can cause a serious condition called Chronic Intestinal Pseudo-Obstruction (CIPO). This happens when the nerves and muscles of the gut stop working properly, creating symptoms of a severe bowel blockage like massive bloating and nausea, even when no physical blockage exists.
Is hearing loss common with MELAS?
Sensorineural hearing loss is very common in MELAS, occurring in up to 78% of cases. It is often progressive over time and may eventually require interventions such as hearing aids or cochlear implants, making regular audiology exams important.
Why do patients with MELAS need kidney and diabetes screening?
The genetic mutation that causes MELAS carries a high risk for developing diabetes and kidney filtering issues over time. Proactive screening helps your care team catch these energy-deficit complications before they cause severe or permanent damage.

Questions for Your Doctor

  • • Which specialists do you recommend we add to our team now, even if I (or my child) don't have symptoms in those areas yet?
  • • How often should we be screening for diabetes and kidney function given the long-term risks of the m.3243A>G mutation?
  • • Can we schedule a baseline echocardiogram and EKG to check for 'silent' heart muscle thickening or electrical issues?
  • • If I (or my child) experience severe bloating or abdominal pain, what is the protocol for checking for intestinal pseudo-obstruction?
  • • Are there local audiologists who have experience working with patients who have mitochondrial-related hearing loss?

Questions for You

  • • Am I experiencing any 'small' digestive issues, like frequent bloating or constipation, that I should mention to my doctor?
  • • Have I noticed any changes in my hearing, especially in noisy environments or when people are speaking softly?
  • • Do I have a primary 'coordinator' for my care who can help all my different specialists share information?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Clinical Characteristics of Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes.

    Fan HC, Lee HF, Yue CT, Chi CS

    Life (Basel, Switzerland) 2021; (11(11)) doi:10.3390/life11111111.

    PMID: 34832987
  2. 2

    MELAS syndrome: Clinical manifestations, pathogenesis, and treatment options.

    El-Hattab AW, Adesina AM, Jones J, Scaglia F

    Molecular genetics and metabolism 2015; (116(1-2)):4-12.

    PMID: 26095523
  3. 3

    A Case Report of a Clinically Suspected Diagnosis of Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes (MELAS) Syndrome With Cardiac Impairment.

    Momoh R, Kollamparambil S

    Cureus 2024; (16(3)):e56980 doi:10.7759/cureus.56980.

    PMID: 38665734
  4. 4

    Late-onset MELAS syndrome in a 46-year-old man with initial symptom of chest tightness: a case report.

    Wang A, Zhao J, Zhao Y, Yan Y

    European heart journal. Case reports 2023; (7(9)):ytad441 doi:10.1093/ehjcr/ytad441.

    PMID: 37767231
  5. 5

    Mitochondrial Cardiomyopathy Presenting as Dilated Phase of Hypertrophic Cardiomyopathy Diagnosed with Histological and Genetic Analyses.

    Kuno T, Imaeda S, Asakawa Y, et al.

    Case reports in cardiology 2017; (2017()):9473917 doi:10.1155/2017/9473917.

    PMID: 28620551
  6. 6

    MELAS and Kearns-Sayre overlap syndrome due to the mtDNA m. A3243G mutation and large-scale mtDNA deletions.

    Yu N, Zhang YF, Zhang K, et al.

    eNeurologicalSci 2016; (4()):15-18 doi:10.1016/j.ensci.2016.04.006.

    PMID: 29430542
  7. 7

    MELAS Syndrome with Cardiac Involvement: A Multimodality Imaging Approach.

    Seitun S, Massobrio L, Rubegni A, et al.

    Case reports in cardiology 2016; (2016()):1490181 doi:10.1155/2016/1490181.

    PMID: 27891257
  8. 8

    Cochlear Implantation in Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes Syndrome: Case Presentation.

    Crundwell G, Kullar P, Bance M

    The journal of international advanced otology 2022; (18(1)):71-73 doi:10.5152/iao.2022.21316.

    PMID: 35193849
  9. 9

    Adult-onset mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS): a diagnostic challenge.

    Acquaah J, Ferdinand P, Roffe C

    BMJ case reports 2024; (17(2)) doi:10.1136/bcr-2023-256306.

    PMID: 38413140
  10. 10

    Retinal multimodal-imaging and functional tests in a mitochondrial disease with focal and segmental glomerulosclerosis.

    Liu XH, Shen X, Zhong YS

    International journal of ophthalmology 2025; (18(9)):1770-1776 doi:10.18240/ijo.2025.09.19.

    PMID: 40881443
  11. 11

    Neovascular Glaucoma in MELAS syndrome.

    Khanna S, Smith BT

    American journal of ophthalmology case reports 2024; (34()):102064 doi:10.1016/j.ajoc.2024.102064.

    PMID: 38707951
  12. 12

    Gastrointestinal Complications of Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS) Syndrome Managed By Parenteral Nutrition.

    Horná S, Péč MJ, Krivuš J, et al.

    European journal of case reports in internal medicine 2024; (11(2)):004268 doi:10.12890/2024_004268.

    PMID: 38352812
  13. 13

    Can Intestinal Pseudo-Obstruction Drive Recurrent Stroke-Like Episodes in Late-Onset MELAS Syndrome? A Case Report and Review of the Literature.

    Gagliardi D, Mauri E, Magri F, et al.

    Frontiers in neurology 2019; (10()):38 doi:10.3389/fneur.2019.00038.

    PMID: 30766507
  14. 14

    Effective Management of Chronic Intestinal Pseudo-Obstruction in MELAS Using Acotiamide: A Case Report.

    Kawano Y, Taniguchi A, Narita Y, et al.

    Case reports in neurology 2024; (16(1)):288-293 doi:10.1159/000541012.

    PMID: 39544351
  15. 15

    A case of exacerbated encephalopathy with stroke-like episodes and lactic acidosis triggered by metformin in a patient with MELAS.

    Shin HJ, Na JH, Lee YM

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2024; (45(5)):2337-2339 doi:10.1007/s10072-024-07343-9.

    PMID: 38265537
  16. 16

    Dynamic derangement in amino acid profile during and after a stroke-like episode in adult-onset mitochondrial disease: a case report.

    Fukuda M, Nagao Y

    Journal of medical case reports 2019; (13(1)):313 doi:10.1186/s13256-019-2255-9.

    PMID: 31630688
  17. 17

    Approach to the Patient - Mitochondrial Diabetes: Contemporary Cases and Precision Medicine Approach.

    Oppenheimer KR, Himelhoch NT, McCullough ME, et al.

    The Journal of clinical endocrinology and metabolism 2025; doi:10.1210/clinem/dgaf698.

    PMID: 41472381
  18. 18

    Fahr Syndrome, Hypoparathyroidism and Mitochondrial Encephalomyopathy With Lactic Acidosis and Stroke-Like Episodes (MELAS) Syndrome.

    Li J, Wang X, Guo Y, et al.

    AACE endocrinology and diabetes 2026; (13(1)):102-106 doi:10.1016/j.aed.2025.09.007.

    PMID: 41641297
  19. 19

    MELAS Syndrome and Kidney Disease Without Fanconi Syndrome or Proteinuria: A Case Report.

    Rudnicki M, Mayr JA, Zschocke J, et al.

    American journal of kidney diseases : the official journal of the National Kidney Foundation 2016; (68(6)):949-953 doi:10.1053/j.ajkd.2016.06.027.

    PMID: 27683045
  20. 20

    Segmental and Focal Glomerulosclerosis Secondary to MELAS Syndrome and Long-Term Outcomes After Kidney Transplant: Case Report and Literature Review.

    de Sousa MV, Mariani G, Ribeiro Alves MAVF, Mazzali M

    Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation 2025; (23(2)):146-150 doi:10.6002/ect.2025.0006.

    PMID: 40094257
  21. 21

    Mitochondrial Encephalomyopathy Lactic Acidosis and Stroke-Like Episodes (MELAS): A Case Report and Critical Reappraisal of Treatment Options.

    Fryer RH, Bain JM, De Vivo DC

    Pediatric neurology 2016; (56()):59-61 doi:10.1016/j.pediatrneurol.2015.12.010.

    PMID: 26797286
  22. 22

    Outcomes misaligned in mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS): implications for trial design.

    Stefanetti RJ, Charman SJ, Newman J, et al.

    Brain communications 2025; (7(5)):fcaf342 doi:10.1093/braincomms/fcaf342.

    PMID: 41048545
  23. 23

    Basic Science and Pathogenesis.

    Mutyala S, Maali LN, Pasya SK

    Alzheimer's & dementia : the journal of the Alzheimer's Association 2025; (21 Suppl 1()):e106536 doi:10.1002/alz70855_106536.

    PMID: 41443978
  24. 24

    Molecular and neurological features of MELAS syndrome in paediatric patients: A case series and review of the literature.

    Seed LM, Dean A, Krishnakumar D, et al.

    Molecular genetics & genomic medicine 2022; (10(7)):e1955 doi:10.1002/mgg3.1955.

    PMID: 35474314
  25. 25

    Atypical clinical manifestation of MT-TL1 mutation in 6 months old patient.

    Janiak J, Piątkowska W, Podlejska P, et al.

    Acta neurologica Belgica 2025; doi:10.1007/s13760-025-02921-w.

    PMID: 41171526
  26. 26

    Acute Management of Neurological Events in Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes (MELAS) Syndrome: A Case Report.

    Aladashvili Z, Rodriguez TB, Izquierdo-Pretel G

    Cureus 2025; (17(5)):e83959 doi:10.7759/cureus.83959.

    PMID: 40502899

This page provides informational guidance on multisystem care and monitoring for MELAS. It does not replace professional medical advice; always consult your specialized care team for personalized screening and treatment plans.

Stay up to date

Get notified when new research about MELAS is published.

No spam. Unsubscribe anytime.